Rigel Pharmaceuticals RIGL Unrealized Losses on Investments (Before Tax)
Unrealized Losses on Investments (Before Tax) at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.
The official record: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rigel Pharmaceuticals's unrealized losses on investments (before tax).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Rigel Pharmaceuticals's unrealized losses on investments (before tax)?
- Rigel Pharmaceuticals (RIGL) reported unrealized losses on investments (before tax) of $170K in Q1 2026.
- What does unrealized losses on investments (before tax) mean?
- This captures the negative change in market value of available-for-sale securities that have not yet been realized through a sale. It serves as an indicator of market volatility impact on the company's balance sheet and potential future impairment risks. High levels of unrealized losses may signal a need for more conservative treasury management.